August 7, 2019

A EAACI drug allergy interest group survey on how European allergy specialists deal with β‐lactam allergy

POSITION PAPER  Free Access

Maria Jose Torres  Gulfem Elif Celik  Paul Whitaker  Marina Atanaskovic‐Markovic  Annick Barbaud Andreas Bircher  Miguel Blanca  Knut Brockow  Jean‐Christoph Caubet  Josefina Rodrigues Cernadas Anca Chiriac  Pascal Demoly  Lene Heise Garvey  Hans F. Merk  Holger Mosbech  Alla Nakonechna Antonino Romano 
Allergy. 2019 Jun;74(6):1052-1062. doi: 10.1111/all.13721
Abstract

An accurate diagnosis of β‐lactam (BL) allergy can reduce patient morbidity and mortality. Our aim was to investigate the availability of BL reagents, their use and test procedures in different parts of Europe, as well as any differences in the diagnostic workups for evaluating subjects with BL hypersensitivity. A survey was emailed to all members of the EAACI Drug Allergy Interest Group (DAIG) between February and April 2016, and the questionnaire was meant to study the management of suspected BL hypersensitivity. The questionnaire was emailed to 82 DAIG centres and answered by 57.

Amoxicillin alone or combined to clavulanic acid were the most commonly involved BL except in the Danish centre, where penicillin V was the most frequently suspected BL. All centres performed an allergy workup in subjects with histories of hypersensitivity to BL: 53 centres (93%) followed DAIG guidelines, two national guidelines and two local guidelines. However, there were deviations from DAIG recommendations concerning allergy tests, especially drug provocation tests. A significant heterogeneity exists in current practice not only among countries, but also among centres within the same country. This suggests the need to re‐evaluate, update and standardize protocols on the management of patients with suspected BL allergy.

No comments:

Post a Comment